Skip to main content

Table 1 Primary characteristics and the results of the applicable studies

From: Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review

Study

Year

Treatment

ORR

DCR

TRAE

Grade ≥ 3 TRAEs

No of response

No of patients

No of response

No of patients

RCTs of early-staged lung cancer

 checkmate159 [24]

2021

nivo

2

22

20

22

23%

4.5%

 IFCT-1601 IONESCO [25]

2017

durva

4

43

37

43

NR

NR

 NADIM [26]

2020

nivo+chemo

36

46

44

46

93%

30%

 NEOSTAR [27]

2020

nivo

5

23

NR

23

NR

13%

nivo+ipi

4

21

NR

21

NR

10%

 SAKK16 14 [21]

2021

durva+chemo

36

62

52

62

NR

88.1%

 PRINCEPS

2020

atezo

16

29

NR

29

NR

NR

 Checkmate-816

2021

nivo+chemo

NR

NR

NR

NR

41%

11%

 IMpower010 [20]

2021

atezo+chemo

NR

NR

NR

NR

93%

22%

 Lcmc3

2021

atezo

NR

NR

NR

NR

67%

16%

RCTs of advanced lung cancer

 KEYNOTE-001 [28]

2019

perm

143

550

490

550

71%

12%

 KEYNOTE-010 [29]

2015

perm-2mg/kg

62

344

NR

344

63%

13%

perm-10mg/kg

64

346

NR

346

66%

16%

 KEYNOTE-021 [14]

2016

perm

33

60

53

60

94%

40%

 KEYNOTE-024 [30]

2016

perm

69

154

NR

154

73.4%

26.6%

 KEYNOTE-042 [31]

2019

perm

174

637

422

637

63%

18%

 CheckMate-026 [15]

2017

nivo

55

211

135

211

71%

18%

 IMpower110 [7]

2010

atezo

81

277

NR

277

90.2%

30.1%

 OAK [11]

2016

atezo

108

622

208

425

64%

15%

 poplar [10]

2016

atezo

96

144

NR

144

67%

40%

 IMpower130 [9]

2019

atezo+chemo

220

447

256

447

96.1%

74.8%

 IMpower131 [8]

2020

atezo+chemo

170

342

277

342

94.6%

69.2%

 IMpower132 [5]

2020

atezo+chemo

137

292

NR

292

91.4%

58.4%

 KEYNOTE-189 [32]

2020

atezo+chemo

195

410

347

410

99.8%

67.2%

 KEYNOTE-407 [6]

2020

atezo+chemo

174

278

239

278

98.6%

74.1%

 Camel [13]

2020

camre

111

205

NR

205

99.5%

68.8%

 Camel-sq

2021

camre

125

193

170

193

100%

80.3%

 Empower-lung1 [4]

2021

cemip

111

283

187

283

57%

14%

 JAVELIN Lung 200 [12]

2018

ave

50

264

136

264

64%

10%

 MYSTIC [33]

2020

durva

66

286

NR

286

54.2%

14.9%

durva+chemo

65

268

NR

268

60.1%

22.9%

 ORIENT-11 [17]

2020

sinti+chemo

138

266

NR

266

99.6%

61.7%

 ORIENT-12 [34]

2021

sinti+chemo

80

179

NR

179

100%

86.6%

 RATIONAL-304 [19]

2021

tisle

128

233

NR

233

100%

33.3%

 RATIONAL-307 [18]

2021

tisle+pc

87

120

105

120

99.2%

85.8%

tisle+nab-pc

89

119

108

119

99.2%

83.9%

 CheckMate 012 [35]

2017

nivo+ipi(12w)

18

38

30

38

82%

37%

nivo+ipi (6w)

15

39

22

39

71%

33%

 CheckMate 017 [36]

2015

nivo

27

135

66

135

58%

7%

 CheckMate 057 [37]

2015

nivo

56

292

130

292

69%

10%

 KEYNOTE-025 [16]

2018

perm

8

37

20

37

87%

29%

 CheckMate 063 [38]

2015

nivo

17

117

47

117

74%

17%

 CheckMate 078 [39]

2018

nivo

56

338

177

338

64%

10%

 IMpower150 [40]

2019

atez+beva+chemo

224

397

335

397

NR

67%

atez+chemo

163

401

317

401

NR

61%

 ARCTIC [41]

2020

durva

22

62

 

62

96.8%

40.3%

 CASPLAN [42]

2019

durva

182

268

202

268

98%

62%

 PROLUNG [43]

2020

perm+chemo

17

40

28

40

NR

NR

 CheckMate 9LA [44]

2021

nivo+ipi+chemo

138

361

302

361

91%

47%

 GARNET

2021

dostar

18

67

NR

67

NR

NR

 CHOICE-01

2021

toripa+chemo

196

309

NR

309

NR

NR

 GEMSTONE-302

2021

sugema+chemo

203

320

NR

320

NR

64.10%

 POSEIDON

2021

durva+chemo

137

338

NR

338

NR

44.60%

durva+treme+chemo

130

338

NR

338

NR

51.80%

 RATIONAL-303

2021

tisle

91

423

NR

423

NR

39%

 CITYCYPE

2021

toripa+atezo

21

67

NR

67

NR

48%

atezo

11

68

NR

68

NR

44%

 AFT-16

2021

atezo+chemo+cCRT

19

62

48

62

87.1%

NR

 PACIFIC [45]

2019

durva

126

443

359

443

96.8%

29.9%

 KEYNOTE-598

2021

pem

129

284

202

284

68.3%

19.6%

pem+ipi

129

284

199

284

76.2%

35.1%

  1. nivo nivolumab, chemo chemotherapy, durva durvalumab, atezo atezolizumab, perm pembrolizumab, ave avelumab, camre camrelizumab, cemip cemiplimab, tisle tislelizumab, sinti sintilimab, ipi ipilimumab, pc paclitaxel and carboplatin, nab nanoparticle albumin-bound, beva bevacizumab, treme tremelimumab, cCRT concurrent chemoradiation therapy, dostar dostarlimab, toripa toripalimab, sugema sugemalimab